{
    "name": "nitisinone",
    "comment": "Rx",
    "other_names": [
        "Orfadin",
        "Nityr"
    ],
    "classes": [
        "Metabolic & Endocrine",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/nityr-orfadin-nitisinone-342859",
    "pregnancy": {
        "common": [
            "Limited data on use in pregnant women insufficiently informs a drug-associated risk of major birth defects and miscarriage"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Reproduction studies were performed in mice at PO doses ~0.4, 4 and 20x the recommended human dose (1 mg/kg/day), nitisinone reported to cause incomplete skeletal ossification of fetal bones, increased gestational length at 4 and 20x the recommended human dose, and decreased pup survival at 0.4x the recommended human dose based on the body surface area",
                    "Studies in rabbits at PO doses ~1.6, 4, and 8x the recommended human dose based on body surface area; nitisinone caused incomplete skeletal ossification of fetal bones"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data on the presence of enasidenib or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production",
            "Data suggest that nitisinone may be present in rat milk due ocular toxicity and lower body weight seen in drug naÃ¯ve pups; consult women of the risk versus benefits for nitisinone and any potential adverse effects on breastfed infant from nitisinone"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May develop transient leukopenia, thrombocytopenia, or both; monitor CBC during therapy",
                "Nitisinone is a moderate CYP2C9 inhibitor, a weak CYP2E1 inducer, and an OAT1/OAT3 inhibitor"
            ],
            "specific": [
                {
                    "type": "Increase tyrosine levels",
                    "description": [
                        "May cause increase in plasma tyrosine levels in patient with HT-1",
                        "Maintain concomitant reduction in dietary tyrosine and phenylalanine during treatment",
                        "Inadequate restriction of tyrosine and phenylalanine may lead to elevated plasma levels of tyrosine",
                        "Do not adjust dosage in order to lower plasma tyrosine concentration; maintain plasma tyrosine levels below 500 micromol/L",
                        "In patients with HT-1 treated with dietary restrictions and receive therapy who develop elevated plasma tyrosine levels, assess dietary tyrosine and phenylalanine intake",
                        "Tyrosine levels >500 mmol/L may lead to",
                        "Variable degrees of intellectual disability and developmental delay; perform a clinical assessment if abrupt changes in neurologic status occur OR ",
                        "Painful hyperkeratotic plaques on the soles and palms OR",
                        "Ocular signs and symptoms (eg, corneal ulcers, corneal opacities, keratitis, conjunctivitis, eye pain, photophobia); rerform a baseline ophthalmologic examination including slit-lamp examination prior to initiating treatment and regularly thereafter; if photophobia, eye pain, or signs of inflammation develops or tyrosine levels are > 500 micromol/L during treatment, undergo slit-lamp reexamination and immediately measure plasma tyrosine concentration"
                    ]
                },
                {
                    "type": "Glycerol content in oral suspension",
                    "description": [
                        "Doses of 20 mL of oral suspension (10 g glycerol) may cause headache, upset stomach and diarrhea due to glycerol content",
                        "Oral suspension contains 500 mg/mL of glycerol",
                        "Consider switching patients who are unable to tolerate the oral suspension to the oral capsules (see Administration)"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Sensitive CYP2C9 substrates or CYP2C9 substrates with a narrow therapeutic index",
                        "Nitisinone increases exposure of CYP2C9 substrates",
                        "Reduce dose of coadministered CYP2C9 substrates drug by half",
                        "Additional dosage adjustments may be needed to maintain therapeutic drug concentrations for narrow therapeutic index drugs; see prescribing information for those drugs",
                        "OAT1/OAT3 substrates",
                        "Nitisinone increases exposure of OAT1/OAT3 substrate Monitor for potential adverse reactions related to coadministered drug "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "nitisinone will increase the level or effect of erdafitinib by  affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. If coadministration of a strong CYP2C9 inhibitors is unavoidable, closely monitor adverse reactions and modify dose of erdafitinib accordingly. If strong CYP2C9 inhibitor is discontinued, consider increasing erdafitinib dose in the absence of any drug-related toxicities."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "nitisinone will increase the level or effect of siponimod by  affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. Coadministration of siponimod with drugs that cause moderate CYP2C9 AND a moderate or strong CYP3A4 inhibition is not recommended. Caution if siponimod coadministered with moderate CYP2C9 inhibitors alone."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosentan",
            "description": {
                "common": "nitisinone will increase the level or effect of bosentan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "nitisinone will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "nitisinone will increase the level or effect of chlorpropamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone",
            "description": {
                "common": "nitisinone will increase the level or effect of dapsone by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "nitisinone will increase the level or effect of diclofenac by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "nitisinone will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "nitisinone will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "nitisinone will increase the level or effect of fluvastatin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "nitisinone will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "nitisinone will increase the level or effect of glimepiride by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "nitisinone will increase the level or effect of glipizide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "nitisinone will increase the level or effect of glyburide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "nitisinone will increase the level or effect of imatinib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketamine",
            "description": {
                "common": "nitisinone will increase the level or effect of ketamine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lacosamide",
            "description": {
                "common": "nitisinone will increase the level or effect of lacosamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lesinurad",
            "description": {
                "common": "nitisinone will increase the level or effect of lesinurad by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "nitisinone will increase the level or effect of losartan by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mestranol",
            "description": {
                "common": "nitisinone will increase the level or effect of mestranol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "montelukast",
            "description": {
                "common": "nitisinone will increase the level or effect of montelukast by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "nitisinone will increase the level or effect of nateglinide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ospemifene",
            "description": {
                "common": "nitisinone will increase the level or effect of ospemifene by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "nitisinone will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propofol",
            "description": {
                "common": "nitisinone will increase the level or effect of propofol by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "nitisinone will increase the level or effect of sulfadiazine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfisoxazole",
            "description": {
                "common": "nitisinone will increase the level or effect of sulfisoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamoxifen",
            "description": {
                "common": "nitisinone will increase the level or effect of tamoxifen by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "nitisinone will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "torsemide",
            "description": {
                "common": "nitisinone will increase the level or effect of torsemide by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "nitisinone will increase the level or effect of trimethoprim by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "nitisinone will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "nitisinone will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zafirlukast",
            "description": {
                "common": "nitisinone will increase the level or effect of zafirlukast by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Liver transplantation",
            "percent": "13"
        },
        {
            "name": "Elevated tyrosine levels",
            "percent": "10"
        },
        {
            "name": "Liver failure",
            "percent": "7"
        },
        {
            "name": "Malignant hepatic neoplasm",
            "percent": "5"
        },
        {
            "name": "Leukopenia",
            "percent": "3"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "3"
        },
        {
            "name": "Conjunctivitis",
            "percent": "2"
        },
        {
            "name": "Corneal opacity",
            "percent": "2"
        },
        {
            "name": "Keratitis",
            "percent": "2"
        },
        {
            "name": "Photophobia",
            "percent": "2"
        },
        {
            "name": "Alopecia",
            "percent": "1"
        },
        {
            "name": "Blepharitis",
            "percent": "1"
        },
        {
            "name": "Cataracts",
            "percent": "1"
        },
        {
            "name": "Dry skin",
            "percent": "1"
        },
        {
            "name": "Epistaxis",
            "percent": "1"
        },
        {
            "name": "Exfoliative dermatitis",
            "percent": "1"
        },
        {
            "name": "Eye pain",
            "percent": "1"
        },
        {
            "name": "Granulocytopenia",
            "percent": "1"
        },
        {
            "name": "Maculopapular rash",
            "percent": "1"
        },
        {
            "name": "Porphyria",
            "percent": "1"
        },
        {
            "name": "Pruritus",
            "percent": "1"
        },
        {
            "name": "Seizure",
            "percent": null
        },
        {
            "name": "Brain tumor",
            "percent": null
        },
        {
            "name": "Encephalopathy",
            "percent": null
        },
        {
            "name": "Hyperkinesia",
            "percent": null
        },
        {
            "name": "Cyanosis",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Enanthema",
            "percent": null
        },
        {
            "name": "Gastrointestinal hemorrhage",
            "percent": null
        },
        {
            "name": "Melena",
            "percent": null
        },
        {
            "name": "Elevated hepatic enzymes",
            "percent": null
        },
        {
            "name": "Liver enlargement hypoglycemia",
            "percent": null
        },
        {
            "name": "Septicemia",
            "percent": null
        },
        {
            "name": "Bronchitis",
            "percent": null
        }
    ]
}